{"nctId":"NCT00897949","briefTitle":"MK0462 in Treatment of Migraine With Recurrence (MK0462-022)","startDateStruct":{"date":"1995-03"},"conditions":["Migraine Headache"],"count":1473,"armGroups":[{"label":"Rizatriptan 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: rizatriptan benzoate (MK0462)"]},{"label":"Rizatriptan 5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: rizatriptan benzoate (MK0462)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: placebo"]}],"interventions":[{"name":"rizatriptan benzoate (MK0462)","otherNames":[]},{"name":"Comparator: placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient had at least a 6-month history of migraine, with or without aura\n* Patient was male, or if female must have been postmenopausal, surgically sterilized, or taking adequate contraceptive precautions\n* Patient was judged to be in good health, apart from migraine\n\nExclusion Criteria:\n\n* Patient was pregnant or a nursing mother\n* Patient had abused drugs or alcohol within 12 months prior to entering the study\n* Patient had a history of cardiovascular disease\n* Patient had clinically significant ECG abnormality\n* Patient had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening\n* Patient received treatment with an investigational device or compound within 30 days of the study start\n* Patient typically suffered from less then 1 or more than 8 attacks of migraine per month\n* Patient had difficulty in distinguishing his/her migraine attacks from tension or interval headaches\n* Patient had prior exposure to rizatriptan","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pain Relief at 2 Hours After the Initial Dose of Test Drug","description":"Patients reporting pain relief (defined as a reduction of headache severity from grades 2/3 at baseline to 0/1) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"285","spread":null},{"groupId":"OG001","value":"322","spread":null},{"groupId":"OG002","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"172","spread":null},{"groupId":"OG001","value":"133","spread":null},{"groupId":"OG002","value":"196","spread":null}]}]}]},{"type":"SECONDARY","title":"Pain Free at 2 Hours After the Initial Dose of Test Drug","description":"Patients reporting pain free (defined as a reduction of headache severity to grade 0 \\[no pain\\]) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"193","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"307","spread":null},{"groupId":"OG001","value":"262","spread":null},{"groupId":"OG002","value":"272","spread":null}]}]}]},{"type":"SECONDARY","title":"No Disability at 2 Hours After the Initial Dose of Test Drug","description":"Patients with no disability at 2 hours after the initial dose of test drug. Functional disability was subjectively rated on a scale from grade 0 to 3: Grade 0 - Normal, Grade 1 - Daily activities mildly impaired, Grade 2 - Daily activities severely impaired, Grade 3 - Unable to carry out daily activities, requires bedrest","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"209","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"148","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"75","spread":null}]}]}]},{"type":"SECONDARY","title":"Use of Escape Medication at 2 Hours After the Initial Dose of Test Drug","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"128","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"357","spread":null},{"groupId":"OG001","value":"380","spread":null},{"groupId":"OG002","value":"176","spread":null}]}]}]},{"type":"SECONDARY","title":"Pain Relief 2 Hours After Treatment for Headache Recurrence","description":"Patients reporting pain relief 2 hours after treatment for headache recurrence (defined as the return of headache to grade 2 or 3 within 24 hours of the initial dose in patients who reported pain relief (grades 0 or 1) at 2 hours).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"53","spread":null},{"groupId":"OG003","value":"33","spread":null},{"groupId":"OG004","value":"12","spread":null},{"groupId":"OG005","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"42","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":456},"commonTop":["Dizziness","Somnolence","Nausea","Asthenia/Fatigue","Paresthesia"]}}}